Occlusive Arterial Disease (OAD) is an indication for drug development with over 50 pipeline drugs currently active. According to GlobalData, preregistered drugs for Occlusive Arterial Disease (OAD) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Occlusive Arterial Disease (OAD) compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Occlusive Arterial Disease (OAD) overview

Occlusive arterial disease (OAD), also known as peripheral arterial disease (PAD) or peripheral vascular disease (PVD), is characterized by the narrowing or blockage of arteries in the extremities, particularly the legs. This occurs due to atherosclerosis, a buildup of plaque made up of cholesterol, fats, calcium, and other substances within the arterial walls. Individuals with OAD may experience symptoms such as leg pain, cramping, or numbness during physical activity (claudication). The pain typically improves with rest but returns upon resuming activity. In severe cases, reduced blood flow can cause tissue damage, leading to non-healing ulcers or even gangrene. Factors contributing to the development of OAD include smoking, diabetes, high blood pressure, high cholesterol, obesity, ssedentary lifestyle, advanced age, and family history of cardiovascular disease.

For a complete picture of PTSR and LoA scores for drugs in Occlusive Arterial Disease (OAD), buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.